Developer docs
API playgroundTry for free, no card

Search company profiles

Heights Capital Management

Full company profile

uuid0003xgr

Namestring
Heights Capital Management
Legal namestring
Heights Capital Management, Inc.
Company typeenum
Private
Founded yearint
1996
Descriptiontext

Heights Capital Management is a private investment firm established in 1996 as an affiliate of Susquehanna International Group LLP, a privately-held global financial services firm founded in 1987 with 3,500+ employees. Heights Capital manages the direct investment of Susquehanna's internal capital through equity and equity-linked instruments in publicly listed companies worldwide, focusing on high-growth firms across biotech, healthcare, technology, financial services, media, energy services, and natural resources. The firm operates as a single direct-investment platform rather than a multi-product manager, with no external limited partners, no fund redemptions, no fundraising pressure, and no sunset dates — a structural feature of the proprietary-capital model.

Operating from offices in San Francisco, the Philadelphia area, Dublin, London, and Hong Kong, Heights Capital deploys capital through direct equity placements, convertible bond financing, and warrant-based equity-linked instruments. The firm invests as a principal, not a fund manager, and targets post-IPO growth companies across the U.S., Europe, and Asia, with affiliated Susquehanna entities providing exchange memberships, market-making infrastructure, and analytical support. Distribution is purely direct: investments are sourced through proprietary deal flow and executed without intermediaries.

Recent deployment illustrates the breadth and scale of the platform. In the 2025-2026 window, Heights Capital led a $200 million combined equity offering and a subsequent $125 million registered direct offering for SEALSQ Corp (post-quantum and quantum security technology), provided €22.5 million in convertible bonds to Nyxoah SA (Belgian medical devices), anchored a €35 million convertible bond arrangement with Faron Pharmaceuticals that grew into a 24.17% voting-rights position via CVI Investments, and participated in financings for GenSight Biologics, IDEX Biometrics, ImmunityBio, and a SPAC stake in Crown Reserve Acquisition Corp. I. The firm has executed hundreds of equity and equity-linked investments in listed companies since inception.

Short descriptiontext

Heights Capital Management is a private investment firm established in 1996 as a Susquehanna International Group affiliate, deploying the parent's proprietary capital into direct equity and equity-linked instruments (including convertible bonds) in high-growth publicly listed companies across biotech, healthcare, technology, and other sectors globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
private equity investments, convertible bond financing, equity-linked investments, growth capital funding, public company investments
Industry1 code
PRIMARYFSANAAAL
Venture Debt Providers
NAICS code1 code
  • Other Financial Investment Activities5239
SIC code1 code
  • Security Brokers, Dealers & Flotation Companies6211
Product category
Private Equity / Growth Capital Investment
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Investment Returns and Capital Gains
TypeTransaction Fee
Description

Heights Capital generates returns through direct equity investments, convertible bonds, and equity-linked instruments in high-growth listed companies worldwide. Returns are realized through capital appreciation, interest payments on convertible bonds, and equity-linked returns.

heightscapital.com
Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Technology or R&D, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Heights Capital Management deploys Susquehanna's proprietary capital into publicly listed high-growth companies worldwide through direct equity investments, convertible bond financing, and equity-linked instruments. The firm focuses on sectors including biotech, healthcare, technology, financial services, media, energy services, and natural resources, providing flexible permanent capital without sunset dates, fund redemptions, or LP fundraising pressure.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Heights Capital Management (HCM) is a private investment firm established in 1996 as an affiliate of Susquehanna International Group LLP. The company manages direct equity and equity-linked investments (including convertible bonds) in high-growth public companies across sectors including biotech, healthcare, technology, financial services, media, energy services, and natural resources. HCM operates as a single investment platform with no distinct product modules—the firm provides flexible, permanent capital to growth-stage companies through various investment structures including equity placements, convertible bond arrangements, and warrant financing. The company has offices in San Francisco, Dublin, London, and Hong Kong serving U.S., European, and Asian markets.

Product and service3 records
1Direct Equity Investments
CategoryEquity Investment
Description

Direct purchases of publicly traded equity in high-growth firms across biotech, healthcare, technology, financial services, media, energy services, and natural resources. Used by publicly listed companies seeking flexible, permanent capital without activist control.

2Convertible Bond Financing
CategoryDebt Financing
Description

Convertible bond issuances provided to publicly listed companies, typically with multi-year maturities and defined interest rates. Used by growth-stage public companies seeking non-dilutive or staged capital that converts into equity.

3Equity-Linked Investments (Warrants and Pre-Funded Warrants)
CategoryStructured Equity Investment
Description

Warrants and pre-funded warrants issued as part of structured equity offerings alongside direct equity or convertible bond placements. Used by publicly listed companies to provide additional upside participation to the investor while supporting the financing round.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Largest publicly traded specialty finance company focused on venture debt to growth-stage, often venture-backed, technology and life-sciences companies; comparable to Heights' growth-stage debt-and-equity-linked capital deployment model.

TypeDirect peer
Description

Specialty venture lending platform providing structured debt to development-stage technology, life-sciences, and healthcare companies, comparable in product structure to Heights Capital's convertible bond financings for growth-stage issuers.

TypeDirect peer
Description

Specialty venture debt provider that supplies senior and convertible debt to growth-stage companies, comparable to Heights Capital's convertible bond financings (e.g., €22.5M for Nyxoah) at a slightly more traditional venture-debt product mix.

TypeBroad incumbent
Description

Investment bank with a dedicated healthcare and growth-company equity capital markets practice that structures and participates in PIPEs and equity-linked offerings, comparable to Heights Capital's PIPE and equity-linked issuance activity in biotech and tech.

TypeDirect peer
Description

Healthcare-focused investment firm that provides PIPE financing and venture debt to biotech and medical-device companies, directly comparable to Heights Capital's biotech-heavy book (Faron, Nyxoah, GenSight, ImmunityBio).

TypeDirect peer
Description

Crossover fund focused on public and late-stage private healthcare and biotech investments, frequently leading PIPE and convertible financings — overlapping directly with Heights Capital's growth-stage life-sciences investment strategy.

TypeBroad incumbent
Description

Diversified financial services firm with a substantial capital markets franchise that arranges and participates in PIPE and registered direct offerings for small- and mid-cap issuers, overlapping with Heights' lead role in SEALSQ's $125M and $200M placements.

TypeBroad incumbent
Description

U.S. investment bank with a strong healthcare and growth-company capital markets franchise that arranges and participates in PIPE and registered direct offerings, comparable to Heights' role as a principal capital provider and lead investor in primary placements.

TypeDirect peer
Description

Specialty healthcare investor providing structured equity and equity-linked capital to public and pre-public life-sciences companies, comparable to Heights' convertible bond and equity-linked financings for emerging biotech and medical-device issuers.

TypeDirect peer
Description

Multi-strategy fund that is a large, active participant in PIPE and equity-linked investments in growth-stage public companies — closely mirroring Heights Capital's core activity of deploying proprietary capital into convertible bonds and equity placements post-IPO.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment36 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Heights Capital Management

Private Equity / Growth Capital Investmentheightscapital.com

Heights Capital Management is a private investment firm established in 1996 as a Susquehanna International Group affiliate, deploying the parent's proprietary capital into direct equity and equity-linked instruments (including convertible bonds) in high-growth publicly listed companies across biotech, healthcare, technology, and other sectors globally.

What Heights Capital Management does

Heights Capital Management is a private investment firm established in 1996 as an affiliate of Susquehanna International Group LLP, a privately-held global financial services firm founded in 1987 with 3,500+ employees. Heights Capital manages the direct investment of Susquehanna's internal capital through equity and equity-linked instruments in publicly listed companies worldwide, focusing on high-growth firms across biotech, healthcare, technology, financial services, media, energy services, and natural resources. The firm operates as a single direct-investment platform rather than a multi-product manager, with no external limited partners, no fund redemptions, no fundraising pressure, and no sunset dates — a structural feature of the proprietary-capital model.

Operating from offices in San Francisco, the Philadelphia area, Dublin, London, and Hong Kong, Heights Capital deploys capital through direct equity placements, convertible bond financing, and warrant-based equity-linked instruments. The firm invests as a principal, not a fund manager, and targets post-IPO growth companies across the U.S., Europe, and Asia, with affiliated Susquehanna entities providing exchange memberships, market-making infrastructure, and analytical support. Distribution is purely direct: investments are sourced through proprietary deal flow and executed without intermediaries.

Recent deployment illustrates the breadth and scale of the platform. In the 2025-2026 window, Heights Capital led a $200 million combined equity offering and a subsequent $125 million registered direct offering for SEALSQ Corp (post-quantum and quantum security technology), provided €22.5 million in convertible bonds to Nyxoah SA (Belgian medical devices), anchored a €35 million convertible bond arrangement with Faron Pharmaceuticals that grew into a 24.17% voting-rights position via CVI Investments, and participated in financings for GenSight Biologics, IDEX Biometrics, ImmunityBio, and a SPAC stake in Crown Reserve Acquisition Corp. I. The firm has executed hundreds of equity and equity-linked investments in listed companies since inception.

Heights Capital Management firmographics

Firmographics
Name
Heights Capital Management
Legal name
Heights Capital Management, Inc.
Website
https://heightscapital.com
Company type
Private
Founded year
1996
Operating status
Operating
Headcount range
11–50 employees
Short description
Heights Capital Management is a private investment firm established in 1996 as a Susquehanna International Group affiliate, deploying the parent's proprietary capital into direct equity and equity-linked instruments (including convertible bonds) in high-growth publicly listed companies across biotech, healthcare, technology, and other sectors globally.
Ownership category
akta.pro rank

Heights Capital Management industry classification

Industry
Product category
Private Equity / Growth Capital Investment
NAICS
Other Financial Investment Activities (5239)
SIC
Security Brokers, Dealers & Flotation Companies (6211)
akta.pro industry
PRIMARYFSANAAAL
Venture Debt Providers

Keywords

  • Private equity investments
  • Convertible bond financing
  • Equity-linked investments
  • Growth capital funding
  • Public company investments

Where Heights Capital Management is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices5 records

Markets served

Heights Capital Management business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure

Revenue model

  1. Investment Returns and Capital Gains: Heights Capital generates returns through direct equity investments, convertible bonds, and equity-linked instruments in high-growth listed companies worldwide. Returns are realized through capital appreciation, interest payments on convertible bonds, and equity-linked returns.

Go-to-market motion1 record

Distribution channels1 record

Heights Capital Management product offering

Product offering

Core offering

Heights Capital Management deploys Susquehanna's proprietary capital into publicly listed high-growth companies worldwide through direct equity investments, convertible bond financing, and equity-linked instruments. The firm focuses on sectors including biotech, healthcare, technology, financial services, media, energy services, and natural resources, providing flexible permanent capital without sunset dates, fund redemptions, or LP fundraising pressure.

Product overview

Heights Capital Management (HCM) is a private investment firm established in 1996 as an affiliate of Susquehanna International Group LLP. The company manages direct equity and equity-linked investments (including convertible bonds) in high-growth public companies across sectors including biotech, healthcare, technology, financial services, media, energy services, and natural resources. HCM operates as a single investment platform with no distinct product modules—the firm provides flexible, permanent capital to growth-stage companies through various investment structures including equity placements, convertible bond arrangements, and warrant financing. The company has offices in San Francisco, Dublin, London, and Hong Kong serving U.S., European, and Asian markets.

Differentiator

Problem solved

Functional benefit

Products and services

  • Direct Equity Investments Direct purchases of publicly traded equity in high-growth firms across biotech, healthcare, technology, financial services, media, energy services, and natural resources. Used by publicly listed companies seeking flexible, permanent capital without activist control.
  • Convertible Bond Financing Convertible bond issuances provided to publicly listed companies, typically with multi-year maturities and defined interest rates. Used by growth-stage public companies seeking non-dilutive or staged capital that converts into equity.
  • Equity-Linked Investments (Warrants and Pre-Funded Warrants) Warrants and pre-funded warrants issued as part of structured equity offerings alongside direct equity or convertible bond placements. Used by publicly listed companies to provide additional upside participation to the investor while supporting the financing round.

Companies that use Heights Capital Management

Customer profile

Named customers6 records

Segments1 record

Ideal customer profiles1 record

Heights Capital Management technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Heights Capital Management partnerships and signals

Strategic signal

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Heights Capital Management competitors and assessment

Company assessment

Direct peers

  • Hercules Capital: Largest publicly traded specialty finance company focused on venture debt to growth-stage, often venture-backed, technology and life-sciences companies; comparable to Heights' growth-stage debt-and-equity-linked capital deployment model.
  • Horizon Technology Finance: Specialty venture lending platform providing structured debt to development-stage technology, life-sciences, and healthcare companies, comparable in product structure to Heights Capital's convertible bond financings for growth-stage issuers.
  • Trinity Capital: Specialty venture debt provider that supplies senior and convertible debt to growth-stage companies, comparable to Heights Capital's convertible bond financings (e.g., €22.5M for Nyxoah) at a slightly more traditional venture-debt product mix.
  • Perceptive Advisors: Healthcare-focused investment firm that provides PIPE financing and venture debt to biotech and medical-device companies, directly comparable to Heights Capital's biotech-heavy book (Faron, Nyxoah, GenSight, ImmunityBio).
  • RA Capital Management: Crossover fund focused on public and late-stage private healthcare and biotech investments, frequently leading PIPE and convertible financings — overlapping directly with Heights Capital's growth-stage life-sciences investment strategy.
  • K2 HealthVentures: Specialty healthcare investor providing structured equity and equity-linked capital to public and pre-public life-sciences companies, comparable to Heights' convertible bond and equity-linked financings for emerging biotech and medical-device issuers.
  • Hudson Bay Capital Management: Multi-strategy fund that is a large, active participant in PIPE and equity-linked investments in growth-stage public companies — closely mirroring Heights Capital's core activity of deploying proprietary capital into convertible bonds and equity placements post-IPO.

Broad incumbents

  • TD Cowen: Investment bank with a dedicated healthcare and growth-company equity capital markets practice that structures and participates in PIPEs and equity-linked offerings, comparable to Heights Capital's PIPE and equity-linked issuance activity in biotech and tech.
  • B. Riley Financial: Diversified financial services firm with a substantial capital markets franchise that arranges and participates in PIPE and registered direct offerings for small- and mid-cap issuers, overlapping with Heights' lead role in SEALSQ's $125M and $200M placements.
  • Piper Sandler: U.S. investment bank with a strong healthcare and growth-company capital markets franchise that arranges and participates in PIPE and registered direct offerings, comparable to Heights' role as a principal capital provider and lead investor in primary placements.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Heights Capital Management financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Heights Capital Management leadership team

Management profile

Number of profiles

Profiles1 record

Heights Capital Management subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Heights Capital Management funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Heights Capital Management M&A and investment

M&A and investment

M&A

Investments36 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Heights Capital Management

What does Heights Capital Management do?

Heights Capital Management deploys Susquehanna's proprietary capital into publicly listed high-growth companies worldwide through direct equity investments, convertible bond financing, and equity-linked instruments. The firm focuses on sectors including biotech, healthcare, technology, financial services, media, energy services, and natural resources, providing flexible permanent capital without sunset dates, fund redemptions, or LP fundraising pressure.

Is Heights Capital Management a public or private company?

Heights Capital Management is a private company. It is classified as corporate owned and is currently operating.

When was Heights Capital Management founded?

Heights Capital Management was founded in 1996. It employs 11 to 50 people.

Where is Heights Capital Management based?

Heights Capital Management is headquartered in San Francisco, United States, in the North America region.

How does Heights Capital Management make money?

One revenue line is on record: investment Returns and Capital Gains.

Who are Heights Capital Management's main competitors?

Direct peers on record are Hercules Capital, Horizon Technology Finance, Trinity Capital, Perceptive Advisors, RA Capital Management, K2 HealthVentures and Hudson Bay Capital Management. Broad incumbents are TD Cowen, B. Riley Financial and Piper Sandler.

Does Heights Capital Management have an API?

No public API is recorded for Heights Capital Management.

What industry is Heights Capital Management in?

Heights Capital Management's product category is Private Equity / Growth Capital Investment. Its primary akta.pro industry code is FSANAAAL, Venture Debt Providers. Its NAICS code is 5239 and its SIC code is 6211.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
American City Business JournalsHeights Capital to invest another $2B in IonQHeights Capital invested another $2 billion in IonQ, its third round in over a year. The firm has backed IonQ with at least $7 billion in total funding.BioSpaceGenSight Biologics Reports Interim Financial Results for the First Half of 2026 and Provides Business UpdatesGenSight Biologics reported H1 2026 IFRS revenue of €(1.2) million, down from €(0.2) million, after collecting €6.5 million in early access payments. Operating cash burn fell 37% to €1.6 million, and manufacturing transfer to Catalent was completed. The company seeks structural financing for the RECOVER Phase III trial, expected to start in H2 2027.MorningstarGenSight Biologics Reports Interim Financial Results for the First Half of 2026 and Provides Business UpdatesGenSight Biologics reported H1 2026 interim results, collecting €6.5M in early access cash but reporting €(1.2)M IFRS revenue after rebates and a €4.3M accounting change. Operating cash burn fell 37% to €1.6M, and manufacturing transfer to Catalent was completed. The company seeks structural financing for the RECOVER Phase III trial, expected to start in H2 2027.Quiver Quantitative$SLDP stock is down 10% today. Here's what we see in our data. | SLDP Stock NewsSundial Growers (SLDP) stock fell 10% on the day with approximately $8.5 million in trading volume, ranking as the 615th most-searched ticker. Recent insider activity shows one sale by LESA B ROE, while institutional investors showed mixed positioning with firms like Heights Capital Management increasing stakes and Nuveen reducing theirs. Analysts have set median price targets at $7.0, with recent ratings from Needham and HC Wainwright & Co.Investing.comFaron Pharmaceuticals receives major holdings notification By Investing.comFaron Pharmaceuticals received notification that Heights Capital Management crossed a major holdings threshold, with its total position decreasing to 24.42% as of May 28, 2026, down from a previous notification of 24.99%. The holdings are held through CVI Investments, Inc., registered in the Cayman Islands, and include voting rights from both direct share ownership and financial instruments including convertible bonds maturing in 2027 and 2028.GlobeNewswireInvitation à assister à l'assemblée générale annuelle et extraordinaire des actionnaires de la Société qui se tiendra le 10 juin 2026Nyxoah SA, a Belgian medical device company listed on Euronext Brussels and Nasdaq (ticker: NYXH), has invited shareholders to its annual and extraordinary general meeting scheduled for June 10, 2026, in Mont-Saint-Guibert, Belgium. The agenda includes approval of the 2025 annual accounts, discharge of directors and the auditor, re-election of six board members including Robelga SRL and five independent directors, appointment of Daniel Wildman, and renewal of the authorized capital framework. The meeting also addresses the terms of 225 convertible bonds issued in December 2025 for a total of 22.5 million euros under a subscription agreement with Heights Capital Management.Quiver QuantitativeSEALSQ Corp Announces $125 Million Securities Offering Led by Heights Capital ManagementSEALSQ Corp announced a $125 million securities offering led by an affiliate of Heights Capital Management, involving the sale of approximately 30.4 million ordinary shares and accompanying warrants. The company intends to use the net proceeds to reinforce its cash position and accelerate the commercialization of its Post-Quantum and Quantum technology in the U.S. and Europe. The transaction is expected to close around March 17, 2026, under an effective shelf registration statement with the SEC.Quiver QuantitativeSEALSQ Corp Announces $125 Million Securities Offering Led by Heights Capital ManagementSEALSQ Corp announced a $125 million securities offering of 30.4 million ordinary shares at $4.11 per share, accompanied by warrants to purchase up to 60.8 million additional shares at $5.50 each, led by Heights Capital Management. The company intends to use the proceeds to strengthen its cash position and accelerate the commercialization of its Post-Quantum and Quantum technology in the United States and Europe. The offering is expected to close on or about March 17, 2026, subject to customary closing conditions.BioSpaceFaron’s Financial Statements Release 1 January to 31 December 2025Faron Pharmaceuticals released its 2025 annual financial statements showing continued clinical and regulatory progress with its lead asset bexmarilimab, including orphan drug designations from both EMA and FDA, positive Phase II BEXMAB trial results presented at major conferences, and constructive feedback from an FDA end-of-phase-II meeting. The company strengthened its financial position through a EUR 12 million private placement and a EUR 35 million convertible bond arrangement with Heights Capital Management, though it reported an operating loss of EUR 19.0 million and negative net assets of EUR -18.5 million as of December 31, 2025. The company announced plans to conduct a rights issue to raise approximately EUR 40 million in 2026 to fund continued development.MorningstarFaron's Financial Statements Release 1 January to 31 December 2025Faron Pharmaceuticals released its 2025 financial statements showing continued advancement of its lead asset bexmarilimab, an immunotherapy candidate for higher-risk myelodysplastic syndrome (HR MDS), with positive clinical data presented at major oncology conferences including ASCO, EHA, ESMO, and ASH. The company strengthened its financial position by raising EUR 12 million through an oversubscribed private placement and EUR 25 million through a convertible bond arrangement with Heights Capital Management, while reporting an operating loss of EUR 19.0 million and negative equity of EUR 18.5 million. Faron received orphan drug designation from both EMA and FDA, held a positive End of Phase 2 meeting with the FDA, and announced plans for a rights issue to raise approximately EUR 40 million, with the directors noting that cash reserves are sufficient only until Q2 2026 without additional financing.